ERES East Resources Acquisition Company

Growing International Pharmaceutical Company Awards $1.2 Million in Studies to eResearchTechnology for Cardiac Safety Monitoring and Information Distribution Services Program Award Includes a Series of Studies Across Several Phases for Multiple Indications in Key Clinical Development Program PHILADELPHIA, March 23 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), , a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that it has been awarded studies totaling approximately $1.2 million in cardiac safety monitoring and services from a growing international pharmaceutical organization for one of its key drugs in clinical trials. The award covers a program of Phase I, Phase II, and Phase IV studies that target several indications and will be conducted at more than 225 research sites distributed across the U.S. eRT will provide comprehensive support and more than 225 units of digital 12-lead ECG equipment designed to facilitate collection of cardiac safety data that is subsequently provided to eRT for analysis. eRT will perform digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT workflow enabled data handlingtechnology, the first solution in production that was designed explicitly to meet emerging international regulatory guidance and technical standards. "eRT is uniquely equipped to collaborate closely with this drug developer in execution of a complex clinical trial program that includes studies spread across several phases, with multiple indications and diverse patient populations," said Scott Grisanti, senior vice president of business development and chief marketing officer at eRT. "Increasingly, pharmaceutical organizations are concluding that such sophisticated programs benefit from a cardiac safety partner with the capacity and scientific capability to deliver a consistent services platform that helps to ensure overall success." Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. The studies pertaining to these awards may be canceled by the sponsor at its sole discretion. As a result, actual results may differ materially from any financial outlooksstated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission. DATASOURCE: eResearchTechnology,Inc. CONTACT: Joan Sterlacci, eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden, Hayden Communications, +1-858-456-4533, for eResearchTechnology Web site: http://www.ert.com/

Copyright